Clinical trial · Observational
EVAluation of Erythrocytosis PRospEctive Cohort STudy
Evaluation of Erythrocytosis Prospective Cohort Study (EVEREST): Diagnosis, Management and Longitudinal Outcomes in Patients with Elevated Hemoglobin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The EValuation of ERythrocytosis pRospEctive cohort STudy (EVEREST) is a prospective study designed to shed light on these key questions in the diagnosis, management, and clinical outcomes in patients with elevated hemoglobin (erythrocytosis). This longitudinal, prospective study will generate high quality data that can help inform the optimal approach to diagnosis and management in this patient population.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Erythrocytosis | — | UNRESOLVED | — |
| Polycythemia | — | UNRESOLVED | — |
| Polycythemia; Familial | — | UNRESOLVED | — |
| Polycythemia, Primary | Polycythemia Vera | ALIAS | 0.90 |
| Polycythemia Secondary | — | UNRESOLVED | — |
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
| Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | ONTOLOGY_EXACT | 0.98 |
| Polycythemia Vera (PV) | Polycythemia Vera | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Erythrocytosis patients
- description
- Adult patients (\>=18 years) referred to hematology clinics at London Health Sciences Centre (LHSC) with erythrocytosis or polycythemia with hemoglobin levels \>=165 g/L in males or \>=160 g/L in females at the time of initial clinic visit.
Primary outcomes (2)
- measure
- Incidence and Causes of Erythrocytosis
- timeFrame
- 5 years
- description
- The study will measure the incidence of primary and secondary causes of erythrocytosis, including polycythemia vera (PV), chronic hypoxia, medication use (e.g., SGLT2 inhibitors, testosterone), and other secondary causes. Data will be derived from clinical records and diagnostic investigations conducted as part of routine care. Unit of Measure: Proportion of participants (%) and count (n) categorized by cause over the study duration.
- measure
- Diagnostic Accuracy of the JAKPOT Prediction Rule
- timeFrame
- 5 years
- description
- The diagnostic accuracy of the JAKPOT prediction rule will be assessed for differentiating JAK2-positive erythrocytosis/PV from other causes. Measures will include sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Unit of Measure: Sensitivity (%), specificity (%), PPV (%), and NPV (%).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients (\>=18 years) referred to hematology clinics at London Health Sciences Centre with hemoglobin levels \>=165 g/L in males or \>=160 g/L in females. 2. Patients capable of providing informed consent. 3. Age \>= 18 years. Exclusion Criteria: 1. Patients \<18 years. 2. Patients without erythrocytosis. 3. Patients incapable of providing informed consent.
References
Publications (0)
Data not yet available